AbbVie (NYSE:ABBV) Shares Down 1.1% – What’s Next?

AbbVie Inc. (NYSE:ABBV) shares were down 1.1% during trading on Friday . The company traded as low as $213.88 and last traded at $214.38. Approximately 7,890,815 shares changed hands during trading, an increase of 5% from the average daily volume of 7,532,547 shares. The stock had previously closed at $216.75.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Topline Phase 3 EPCORE DLBCL‑1 results for epcoritamab announced; AbbVie and partner Genmab will engage global regulators on next steps — a clear near‑term commercialization pathway if regulators agree, which supports revenue upside for ABBV’s oncology franchise. PR Newswire: EPCORE topline
• Positive Sentiment: Analyst model upgrades from Zacks: multiple raises to AbbVie’s quarterly and full‑year EPS estimates (FY2026/2027), which can lift sentiment and support higher analyst targets. (Market estimates revisions typically help investor confidence.)
• Positive Sentiment: Pipeline expansion: AbbVie launched first‑in‑human trial for ABBV‑711 (advanced squamous tumors) and reported completion/advancement of other early‑stage programs (including obesity candidate GUB014295 and ABBV‑CLS‑616), diversifying long‑term growth drivers beyond immunology. TipRanks: ABBV‑711 trial
• Neutral Sentiment: Unusually large call‑option activity: a ~2,600% spike in call volume indicates large investors are betting on upside around upcoming catalysts (earnings, regulatory decisions). This is a market signal rather than a fundamental result — it can amplify moves but is not a direct business update. MarketBeat: options spike
• Negative Sentiment: Counterpoint risk: Seeking Alpha reported shares of Genmab fell on trial data for Epkinly (an AbbVie‑partnered B‑cell lymphoma program), which may have created cross‑party market jitters and pressured biotech sector sentiment — any negative readthrough to AbbVie’s partnered assets can weigh on ABBV stock short‑term. Seeking Alpha: Genmab/Epkinly
• Negative Sentiment: Near‑term market weakness: coverage note (Zacks) flagged a recent intraday dip in ABBV while the broader market gained, highlighting investor profit‑taking or rotation despite positive fundamentals. Zacks: stock dip

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ABBV shares. BMO Capital Markets reiterated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research report on Thursday. Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and upped their target price for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Finally, Morgan Stanley lifted their price target on shares of AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $247.84.

AbbVie Price Performance

The firm’s 50 day moving average is $226.89 and its 200 day moving average is $216.08. The company has a market capitalization of $378.89 billion, a PE ratio of 162.41, a P/E/G ratio of 0.91 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is currently 496.97%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ABBV. Norges Bank bought a new position in shares of AbbVie in the second quarter worth about $4,288,200,000. Wellington Management Group LLP boosted its stake in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Laurel Wealth Advisors LLC boosted its stake in AbbVie by 18,384.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after purchasing an additional 5,675,095 shares during the period. Assenagon Asset Management S.A. grew its holdings in AbbVie by 550.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after buying an additional 3,666,521 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after buying an additional 3,380,842 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.